DKDavid T. Kuchiev

David T. Kuchiev

*This is an algorithmically generated author record based on publicly available information.

David T. Kuchiev has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of сomprehensive cardio-oncological rehabilitation programs on the psychological status of breast cancer survivors: a pilot randomized study

    by Marina V. Vitsenya, Irina V. Barinova, Nana V. Pogosova, Tatevik A. Terteryan, David T. Kuchiev, Anna A. Gerasimova, Anastasiya Y. Filatova, Nursiyat M. Ibragimova, Olga O. Frolkova, Fail T. Ageev

    Background: Psychological abnormalities are common among breast cancer (BC) survivors and may negatively impact their quality of life and outcomes. An improvement in the psychosocial well-being of cancer patients is a key objective of comprehensive cardio-oncology rehabilitation (CORE) programs. Remote CORE models could contribute to increased patient involvement in such programs. Aim: To compare the effectiveness of the off-line (Off-L) and online (On-L) CORE programs regarding their effects on the psychological status parameters in ВС survivors. Methods: This single center pilot randomized prospective study was conducted in a total of 90 BC survivors from 2021 to 2023 in a specialized cardiology clinic. The patients were randomized into three parallel groups in 1:1:1 ratio: the Off-L cardiac rehabilitation program group, the On-L cardiac rehabilitation program group, and the control group. The CORE programs included an educational component addressing cardiovascular risk factors with nutritional counseling, a supervised individualized twice weekly physical exercise program for 3 months (Off-L group), an individualized home-based physical exercise regimen with remote support for 3 months (On-L group), and psychological support with a single session with a psychologist. The control group patients were followed up in their routine clinical practice. In all patients, past history data were collected, including educational level and marital status. Baseline assessments and follow-up evaluation at 6 months included clinical characteristics, stress levels (visual analog scale, VAS), anxiety and depression scores (Hospital Anxiety and Depression Scale, HADS), sleep quality (Pittsburgh Sleep Quality Index), and cognitive function (Montreal Cognitive Assessment, MoCA). Results: The patients median age was 49 years [IQR 46; 56]. At baseline, anxiety symptoms (AS) were found in 45 (50%) patients, depressive symptoms (DS) in 16 (17.8%), high stress levels in 51 (56.7%), sleep disturbances in 80 (89%), and cognitive impairment in 11 (12.4%) patients. There were no differences at baseline between the groups in their main characteristics studied. Over the 6-month follow up, 23 patients dropped from the study. By the end of the observation period, the CORE groups showed a decrease in AS in the Off-L group (n = 20) from 8.5 [6.0; 10.0] to 6.0 [4.0; 9.5] points, with the difference in their median values of -1.5 (95% confidence interval [CI]: -3.0, -0.5, p = 0.026) and in the On-L group from 7.0 [5.0; 8.0] to 5.0 [3.0; 8.0] points (the difference in median values: -2.0, 95% CI: -3.0, 0.5, р = 0.018). No significant changes in AS were found in the control group (the difference in median values: -0.5, 95% CI: -2.0, 0.5, p = 0.181). In the patients with baseline subclinical (8 to 10 points, HADS-A) and clinically significant (≥ 11 points) anxiety, the participation in the CORE programs have led to a higher chance of its decrease either to 8 points or a change in the anxiety category from clinically overt to subclinical (odds ratio 5.667, 95% CI: 1.129, 28.455, р = 0.035). By the end of the follow up, the stress levels in the Off-L group decreased from 8.0 [5.0; 9.0] to 7.0 [4.0; 8.0] VAS points (the difference of the medians: -1.5, 95% CI: -2.0, 0.0, р = 0.050), in the On-L group from 7.0 [6.0; 8.0] to 5.0 [4.0; 6.8] points (the difference of the medians: -1.5, 95% CI: -2.5, -0.5, р = 0.003). There were no significant changes over time in the stress levels in the control group (the difference of the medians: 0.0, 95% CI: -1.0, 1.0, р = 0.974). No statistically significant changes were found in depression scores or sleep quality over the 6-month observation period in the study groups. The On-L group demonstrated a statistically significant improvement in the MoCA cognitive function scores (the difference of the medians: 0.5, 95% CI: 0.0, 1.0, р = 0.021). Conclusion: The participation of BC survivors in the CORE programs facilitates the decrease in anxiety and stress. The On-L CORE program is not inferior to the Off-L program in its impact on the patients’ psychological status. In this regard, further larger studies on the effectiveness of CORE models with various type of telemedicine support seem promising in this patient population.


  • Open Access

    Prevalence of cardiovascular diseases and risk factor assessment in breast cancer survivors exposed to cardiotoxic therapy

    by Marina V. Vitsenya, Irina V. Barinova, Nana V. Pogosova, Tatevik A. Terteryan, David T. Kuchiev, Yulia V. Khrushcheva, Anna A. Gerasimova, Anastasiya Y. Filatova, Nursiyat M. Ibragimova, Olga O. Frolkova, et al.

    Background: Patients having been treated for breast cancer (BC) are at increased risk of cardiovascular disease (CVD). Participation of patients with high cardiovascular risk (CVR) in comprehensive cardiac rehabilitation programs seems to be a promising area of prevention; however, at present there is no understanding of the scope of the need for such programs in Russia. Aim: To evaluate the frequency of CVDs and their risk factors, and total CVR in BC patients who have undergone cardiotoxic antitumor treatment to determine the need for the development of cardiac rehabilitation programs in this patient category. Methods: This was a single center cross-sectional study performed in 2021 to 2023 in a specialized cardiology clinic in 90 women who had undergone cardiotoxic breast cancer therapy. The patients were examined for CVDs and their risk factors, with assessment of clinical status, serum lipids, glucose, creatinine, and C-reactive protein, levels of physical activity (International Physical Activity Questionnaire), stress (Visual Analog Scale), anxiety and depression (Hospital Anxiety and Depression Scale, HADS), and sleep quality (Pittsburgh Sleep Quality Questionnaire). Electrocardiography (ECG), echocardiography, exercise tolerance ECG test, including cardiorespiratory exercise test (n = 53), and bioimpedancemetry (n = 83) were also performed. Results: The median patient age was 49 [46; 56] years. All patients (100%) had undergone surgery and anthracycline-based chemotherapy. The median time after the end of anthracycline-based chemotherapy was 36 [11.8; 56.5] months. Radiation therapy had been performed in 68 (75.6%) patients, including 42 patients with left-sided BC. Nine (10%) patients were smokers, 52 (57.8%) were overweight or obese, 37 (41.1%) had abdominal obesity, 70 (77.8%) dyslipidemia, 42 (46.7%) arterial hypertension, and 6 (6.7%) diabetes mellitus. Insufficient physical activity was reported by 69 (76.7%) patients. The cardiorespiratory endurance was reduced, with median peak oxygen consumption being 71% of the predicted values. Anxiety symptoms were found in 45 (50%) patients, depressive symptoms in 16 (17.8%), high stress levels in 51 (56.7%), and sleep disorders in 80 (88.9%). Heart failure was diagnosed in 11 (12.2%) patients, coronary heart disease in 1 (1.1%), and paroxysmal atrial fibrillation in 3 (3.3%). Fifty six (56, 62.2%) patients had a high/very high CVR (according to the 2022 ESC Guidelines on cardio-oncology). Conclusion: There is a high prevalence of cardiovascular risk factors in the patients who underwent cardiotoxic antitumor treatment for BC. The most frequent CVD was heart failure; two thirds of the patients had a high cardiovascular risk. Given the prevalence of BC in Russia, there is a clear need to develop programs for cardiac rehabilitation and CVD prevention in this patient category.


  • Open Access

    Association of cardiovascular disease with hospital mortality in COVID-19 patients

    by N. V. Pogosova, M. V. Ezhov, I. V. Barinova, A. K. Ausheva, D. T. Kuchiev, A. B. Popova, A. A. Arutyunov, S. A. Boytsov

    Aim. To evaluate the relationship between the in-hospital mortality of patients with COVID-19 and the history of cardiovascular disease (CVD) using data from the Russian registry of patients with COVID-19. Material and methods. This study included 758 patients with COVID-19 (403 men, 355 women) aged from 18 to 95 years (median, 61 years), successively hospitalized in the COVID hospital of the Chazov National Medical Research Center of Cardiology from April through June 2020. Death predictors were studied using single- and multivariate regression analyses with the SPSS Statistics, Version 23.0 software. Results. During the stay in the hospital, 59 (7.8 %) patients with COVID-19 died, 677 (89.3 %) were discharged, and 22 (2.9 %) were transferred to other hospitals. The univariate regression analysis showed that the increase in age per decade was associated with a 92% increase in the risk of death [relative risk (RR), 1.92; 95% confidence interval (CI), 1.58-2.34; p Conclusion. A history of CVD and the CVD number and severity are associated with a higher risk of death during the hospitalization for COVID-19; the independent predictors of in-hospital death are an age of 80 years and older and CHF.


  • Clinical, instrumental and laboratory data on consequences of COVID-19 in delayed period after admission

    by N.V. Pogosova, D.T. Kuchiev, A.B. Popova, A.K. Ausheva, R.A. Zhetisheva, I.V. Barinova, T.V. Balakhonova, N.V. Gomyranova, A.N. Rogoza, M.A. Shariya, et al.

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить последствия COVID-19 у госпитализированных пациентов через 3—7 мес после выписки из стационара по данным клинико-инструментальных и лабораторных методов исследования. МАТЕРИАЛ И МЕТОДЫ В исследование включены пациенты, прошедшие стационарное лечение в COVID-центре ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России (за период с апреля по июнь 2020 г.) и согласившиеся принять участие в программе амбулаторного обследования «COVID-19 — отдаленное наблюдение» через 3—7 мес после выписки. Всем участвующим в программе пациентам (n=213) на амбулаторном этапе был проведен комплекс лабораторных методов обследования (общеклинический анализ крови, биохимический анализ крови, высокочувствительный тропонин I, высокочувствительный С-реактивный белок (вчСРБ), Д-димер, N-концевой фрагмент предшественника мозгового натрийуретического гормона (NT-proBNP) регистрировалась электрокардиография (ЭКГ), проводилась эхокардиография (ЭхоКГ). Холтеровское мониторирование ЭКГ (ХМ ЭКГ) и дуплексное сканирование вен нижних конечностей проводили пациентам, которым исследования выполнялись в остром периоде заболевания COVID-19. Магнитно-резонансная томография (МРТ) сердца с отсроченным контрастированием проводилась пациентам, у которых концентрация тропонина I в остром периоде заболевания COVID-19 имела десятикратное превышение 99 процентиля. РЕЗУЛЬТАТЫ В исследование включено 213 пациентов (55,4% мужчин, медиана возраста 57 [49; 64] лет). По данным общего анализа крови, у преобладающего большинства пациентов показатели были в пределах нормальных значений, однако до 10% включенных лиц имели анемию (легкой степени), нейтропению, лимфопению. В биохимическом анализе крови обращали на себя внимание повышенный уровень NT-proBNP у 70 (32,9%) человек, вчСРБ у 35 (16,4%), Д-димера у 32 (15,1%) и тропонина I у 14 (6,6%) пациентов. Снижение скорости клубочковой фильтрации менее 60 мл/мин/1,73 м2 было выявлено у 16 (7,5%) пациентов. По данным ЭКГ, нарушения ритма сердца были зарегистрированы у 25 (11,8%) пациентов. Нарушение проводимости сердца в виде блокады ножек пучка Гиса регистрировалось почти у половины пациентов (47,6%). Изменения сегмента ST в виде депрессии, элевации было зарегистрировано у 33 (15,6%) пациентов. При анализе данных ХМ ЭКГ нарушения ритма сердца (фибрилляция предсердий, пробежки наджелудочковой тахикардии и желудочковой тахикардии) в остром периоде инфекции были зарегистрированы у 14 (61%) пациентов (n=23), тогда как через 3—7 мес после выписки из COVID-центра — у 18 (78%) пациентов. Достоверно чаще регистрировались неустойчивые пробежки наджелудочковой тахикардии в постковидном периоде (p=0,01). Значимых пауз и изменений сегмента ST зарегистрировано не было. По данным ЭхоКГ нарушения локальной сократимости выявлены у 12 (5,7%) пациентов. Ни у одного из включенных нами пациентов не было клинических признаков, позволяющих заподозрить перенесенный миокардит. По результатам МРТ сердца с гадолинием (n=5) ни у одного больного данных за острый миокардит и поствоспалительные фиброзные изменения миокарда в отдаленном периоде не подтвердились. При ДС вен нижних конечностей в остром периоде инфекции (n=24) у 29,2% были выявлены изменения: у 3 (12,5%) человек — признаки флебита, еще у 1 (4,2%) — посттромбофлебитический синдром (ПТФС) и у 2 (8,3%) — признаки тромбоза, а у 1 (4,2%) пациента выявлены признаки тромбоза в сочетании с ПТФС. У 70,8% пациентов патологии вен нижних конечностей не выявлено. В отдаленном периоде наблюдения только у одного пациента признаки тромбоза вен нижних конечностей выявлены впервые. ЗАКЛЮЧЕНИЕ Представленные данные свидетельствуют о наличии изменений по данным клинико-инструментальных и лабораторных методов исследования у пациентов, перенесших COVID-19. Дальнейшее изучение постковидного синдрома, его клинических проявлений и патофизиологических механизмов является одной из важнейших задач для общественного здравоохранения.


  • Open Access

    Sequelae of COVID-19 at long-term follow-up after hospitalization

    by N. V. Pogosova, F. N. Paleev, A. K. Ausheva, D. T. Kuchiev, S. A. Gaman, T. N. Veselova, M. B. Belkind, O. Yu. Sokolova, R. A. Zhetisheva, S. K. Ternovoy, et al.

    Aim. To assess long-term sequelae of COVID-19 in hospitalized patients at 3 to 7 months after discharge.Material and Methods. The whole of 700 patients hospitalized to the temporary COVID-19 treatment center hosted by the FSBI “National Medical Research Center of Cardiology” of the Ministry of Health of Russia from April to June 2020 were invited to participate in a follow-up study. At 3-7 months after the index hospitalization, patients or their proxies were contacted via telephone in order to obtain information on their vital status, cardiovascular and other conditions or their complications, and new hospitalizations. In addition, patients were invited to an outpatient visit under the "COVID-19-follow-up" program, encompassing physical examination and a comprehensive battery of laboratory and instrumental tests, including spirometry, chest computed tomography (CT) and the six minute walk test (6MWT). Further, dyspnea was assessed using the mMRC (Modified Medical Research Council) Dyspnea Scale. Results: We were able to contact 87.4% (612/700) of patients or their proxies. At follow-up, 4.4% (27) patients died, of which 96.3% (26) had cardiovascular diseases (CVD). A total of 213 patients aged 19 to 94 years old (mean age 56.8±12.5, median 57 years [49.0; 64.0]; men, 55.4%) agreed come for an outpatient visit and to participate in the “COVID-19-follow-up” program. Since discharge, 8% (17) of patients required new hospitalizations, and more than a half of these patients (58.8%; 10/17) had CVD-related hospitalizations. A total of 8.4% (18) patients experienced worsening of hypertension, 9 (4.2%) patients had newly diagnosed hypertension, 2 (0.9%) – coronary artery disease patients experienced new/recurrent angina symptoms. 4 (1.9%) patients had newly diagnosed coronary artery disease, and one patient had an ischemic stroke. At the outpatient visit, 114 (53.5%) patients had some symptoms, most frequently, shortness of breath (33%), fatigue (27.4%), chest pain (11.3%), and abnormal heartbeats (8.5%). Based on the mMRC Scale, 59% of patients had dyspnea of varying severity. Most patients had a normal vital capacity (VC), which was moderately reduced in 3.3% and severely reduced in 0.5% of patients. Chest CT scans were obtained in 78 (36.6%) patients, whose worst lung damage scores during hospitalization were CT3 or CT4. One in ten patients (10.8%) with severe lung damage during acute infection had persisting ground glass opacities, 35.9% developed fibrotic changes, 79.6% of patients had linear or fine focal opacities. According to the 6MWT data, 12.3% of patients walked less than 70% of the predicted distance, 67% walked 71 to 99% of the predicted distance, and 20.7% of patients were able to walk 100% of their predicted distance.Conclusion. These data suggest long-term negative sequelae of COVID-19 in more than half of hospitalized patients.